glp 1 agonist diabetes Understanding GLP-1 receptor agonists and their impact on drug discovery Dual GIP/GLP-1 receptor agonists: New

For patients who have not responded well to semaglutide or tirzepatide, or who have specific reasons to prefer a daily liraglutide regimen, Saxenda remains a valid clinical option

However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies

(2021) 12:721135/XML/NLM

Weight loss and diabetes can be a very daunting experience, hence the most effective bariatric surgery options are always far beyond physical injections

M.et al (2021)

An athlete needing dialysis treatment requires a Therapeutic Use Exemption